PD

Paul Da Silva Jardine

Venture Partner at Apple Tree Partners

Guilford, Connecticut

Overview 

Paul Da Silva Jardine is a Venture Partner at Apple Tree Partners, with a background in the pharmaceutical industry and expertise in areas such as biotechnology, clinical trials, and drug development. He has held key roles at Staten Biotechnology and Pfizer, where he served as Chief Scientific Officer and Vice President in various research and development capacities. Jardine's career highlights include leading research teams at Pfizer in cardiovascular and metabolic diseases, as well as making strategic investments in companies like Red Queen Therapeutics, Deep Apple Therapeutics, and Aethon Therapeutics at Apple Tree Partners.

Work Experience 

  • Venture Partner

    2021 - Current

  • Chief Scientific Officer

    2015

    Staten Biotechnology is a Precision Medicine Cardiovascular and Dyslipidemic company for targets with robust human genetics support

  • Vice President Cardiovascular and Metabolic Research

    2009 - 2015

  • Vice President, Head of Cardiovascular and Metabolic and Endocrine Diseases Chemistry

    2004 - 2009

  • Senior Director, Head of Obesity and Osteoporosis Chemistry CVMED

    2001 - 2004

  • Research Scientist to Director Chemistry

    1989 - 2001

Pfizer is a biopharmaceutical company that provides affordable access to safe, effective medicines and health care services.

Raised $32,000,000,000.00 from Starboard Value.

Articles About Paul

Relevant Websites